Poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) are targeted drugs used for the treatment of homologous recombination repair (HR)-defective tumours that have demonstrated antitumoral activity in several cancers harbouring germline and somatic BRCA1/2 mutations [1]. The gene discussed is BRCA1; the disease is neoplasm.